A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...
This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...
In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback